## Wei-Dong Chen

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9778001/publications.pdf

Version: 2024-02-01

331670 330143 1,917 37 21 37 citations h-index g-index papers 37 37 37 3048 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	LRP5 promotes cancer stem cell traits and chemoresistance in colorectal cancer. Journal of Cellular and Molecular Medicine, 2022, 26, 1095-1112.	3.6	9
2	Design, synthesis and evaluation of 3-phenoxypyrazine-2-carboxamide derivatives as potent TGR5 agonists. RSC Advances, 2022, 12, 3618-3629.	3.6	1
3	LRP5 Promotes Gastric Cancer via Activating Canonical Wnt/ $\hat{l}^2$ -Catenin and Glycolysis Pathways. American Journal of Pathology, 2022, 192, 503-517.	3.8	11
4	HGF/c-Met: A Key Promoter in Liver Regeneration. Frontiers in Pharmacology, 2022, 13, 808855.	3.5	26
5	Design, synthesis and evaluation of 1-benzyl-1H-imidazole-5-carboxamide derivatives as potent TGR5 agonists. Bioorganic and Medicinal Chemistry, 2021, 32, 115972.	3.0	4
6	The complex role of Wnt ligands in type 2 diabetes mellitus and related complications. Journal of Cellular and Molecular Medicine, 2021, 25, 6479-6495.	3.6	34
7	Activation of FXR Suppresses Esophageal Squamous Cell Carcinoma Through Antagonizing ERK1/2 Signaling Pathway. Cancer Management and Research, 2021, Volume 13, 5907-5918.	1.9	7
8	Ligand-based pharmacophore modeling, virtual screening and biological evaluation to identify novel TGR5 agonists. RSC Advances, 2021, 11, 9403-9409.	3.6	14
9	Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists. RSC Advances, 2021, 11, 2158-2166.	3.6	2
10	miRNA-382-5p Suppresses the Expression of Farnesoid X Receptor to Promote Progression of Liver Cancer. Cancer Management and Research, 2021, Volume 13, 8025-8035.	1.9	9
11	Nuclear receptors: a bridge linking the gut microbiome and the host. Molecular Medicine, 2021, 27, 144.	4.4	11
12	Emerging Role of Non-Coding RNAs in Esophageal Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2020, 21, 258.	4.1	57
13	miR-149* Suppresses Liver Cancer Progression by Down-Regulating Tumor Necrosis Factor Receptor 1–Associated Death Domain Protein Expression. American Journal of Pathology, 2020, 190, 469-483.	3.8	18
14	The roles of the gut microbiota–miRNA interaction in the host pathophysiology. Molecular Medicine, 2020, 26, 101.	4.4	45
15	Emerging Roles of Wnt Ligands in Human Colorectal Cancer. Frontiers in Oncology, 2020, 10, 1341.	2.8	85
16	The Relationship Between Gut Microbiota and Inflammatory Diseases: The Role of Macrophages. Frontiers in Microbiology, 2020, 11, 1065.	3.5	146
17	The Apelin/APJ System in Psychosis and Neuropathy. Frontiers in Pharmacology, 2020, 11, 320.	3.5	30
18	Farnesoid X receptor: a potential therapeutic target in multiple organs. Histology and Histopathology, 2020, 35, 1403-1414.	0.7	7

#	Article	IF	Citations
19	Downregulation of Wnt3 Suppresses Colorectal Cancer Development Through Inhibiting Cell Proliferation and Migration. Frontiers in Pharmacology, 2019, 10, 1110.	3.5	23
20	Spexin/NPQ Induces FBJ Osteosarcoma Oncogene (Fos) and Produces Antinociceptive Effect against Inflammatory Pain in the Mouse Model. American Journal of Pathology, 2019, 189, 886-899.	3.8	17
21	Emerging Roles of NPQ/Spexin in Physiology and Pathology. Frontiers in Pharmacology, 2019, 10, 457.	3.5	50
22	HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers. International Journal of Molecular Sciences, 2018, 19, 3295.	4.1	37
23	Interplay of miRNAs and Canonical Wnt Signaling Pathway in Hepatocellular Carcinoma. Frontiers in Pharmacology, 2018, 9, 657.	3.5	22
24	Gut Microbiota: An Integral Moderator in Health and Disease. Frontiers in Microbiology, 2018, 9, 151.	3.5	306
25	Quercetin Inhibits LPS-Induced Inflammation and ox-LDL-Induced Lipid Deposition. Frontiers in Pharmacology, 2017, 8, 40.	3.5	52
26	The Role of the Apelin/APJ System in the Regulation of Liver Disease. Frontiers in Pharmacology, 2017, 8, 221.	3.5	32
27	DAF-16/FOXO Transcription Factor in Aging and Longevity. Frontiers in Pharmacology, 2017, 8, 548.	3.5	166
28	The G-protein-coupled bile acid receptor Gpbar1 (TGR5) protects against renal inflammation and renal cancer cell proliferation and migration through antagonizing NF-κB and STAT3 signaling pathways. Oncotarget, 2017, 8, 54378-54387.	1.8	33
29	MicroRNA-149* suppresses hepatic inflammatory response through antagonizing STAT3 signaling pathway. Oncotarget, 2017, 8, 65397-65406.	1.8	18
30	Apelin/APJ system: A key therapeutic target for liver disease. Oncotarget, 2017, 8, 112145-112151.	1.8	32
31	Downregulation of human Wnt3 in gastric cancer suppresses cell proliferation and induces apoptosis. OncoTargets and Therapy, 2016, Volume 9, 3849-3860.	2.0	28
32	TGR5, Not Only a Metabolic Regulator. Frontiers in Physiology, 2016, 7, 646.	2.8	148
33	β-Amyloid: the key peptide in the pathogenesis of Alzheimer's disease. Frontiers in Pharmacology, 2015, 6, 221.	3.5	216
34	The G-Protein-Coupled Bile Acid Receptor Gpbar1 (TGR5) Inhibits Gastric Inflammation Through Antagonizing NF-κB Signaling Pathway. Frontiers in Pharmacology, 2015, 6, 287.	3.5	81
35	Farnesoid X Receptor Antagonizes JNK Signaling Pathway in Liver Carcinogenesis by Activating SOD3. Molecular Endocrinology, 2015, 29, 322-331.	3.7	38
36	The G-protein-coupled bile acid receptor Gpbar1 (TGR5) suppresses gastric cancer cell proliferation and migration through antagonizing STAT3 signaling pathway. Oncotarget, 2015, 6, 34402-34413.	1.8	47

#	Article	lF	CITATIONS
37	Farnesoid X Receptor Protects Liver Cells from Apoptosis Induced by Serum Deprivation in Vitro and Fasting in Vivo. Molecular Endocrinology, 2008, 22, 1622-1632.	3.7	55